Loading clinical trials...
Loading clinical trials...
This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with relapsed multiple myeloma...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Seagen Inc.
Collaborators
NCT07053436 · High Risk Newly Diagnosed Multiple Myeloma
NCT06615479 · Relapsed or Refractory Multiple Myeloma (RRMM)
NCT07030517 · Multiple Myeloma
NCT02269592 · Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, and more
NCT06106945 · Multiple Myeloma
Rocky Mountain Cancer Center
Denver, Colorado
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
Dana Farber Cancer Institute
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions